News | May 08, 2026
Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Advances clinical research capabilities with leading regulatory grade registries platform
Subscribe To Our Newsletter & Stay Updated
